OTCMKTS:GMXAY GENMAB A/S/S (GMXAY) Stock Price, News & Analysis $28.38 +0.25 (+0.89%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$28.14▼$28.4750-Day Range$24.85▼$29.9852-Week Range$12.10▼$19.00Volume609,703 shsAverage Volume48,553 shsMarket CapitalizationN/AP/E Ratio10.89Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get GENMAB A/S/S alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About GENMAB A/S/S Stock (OTCMKTS:GMXAY)Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.Read More GMXAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMXAY Stock News HeadlinesJuly 17, 2024 | americanbankingnews.comGENMAB A/S/S (OTCMKTS:GMXAY) Share Price Crosses Below Fifty Day Moving Average of $27.33April 30, 2024 | markets.businessinsider.comDecoding 9 Analyst Evaluations For GenmabJuly 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.April 28, 2024 | msn.comMeet the Genesis Electrified G80 Magma: A Sleek and Speedy ConceptApril 26, 2024 | msn.com2026 Genesis GV70 Will Be Updated with a Huge New Screen InsideApril 26, 2024 | yahoo.comHow an Album From 1977 Became a Gen Z TouchstoneApril 20, 2024 | msn.comAs lead gen grows on social media, marketers discuss what’s workingApril 17, 2024 | msn.comWhat will RenCen be used for once GM moves headquarters to Hudson's site?July 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.April 12, 2024 | yahoo.comThe Comics History Behind Genosha, Marvel's Fallen Mutant HavenApril 12, 2024 | msn.comGene variant may protect against Alzheimer'sApril 4, 2024 | msn.comGen X only has $108,600 saved for retirement — but they think they'll need $1.45 million more to live comfortably, a survey foundApril 1, 2024 | msn.com'No one can replace him': Internet abuzz as 'Gen V' Season 2 filming delayed indefinitely following Chance Perdomo's deathApril 1, 2024 | msn.comSeoul’s Glimpse into Automotive History with a Vintage BMW AppearanceMarch 31, 2024 | msn.comAudacious XM a change of direction for BMW’s M divisionMarch 31, 2024 | msn.comGen Z’s Behavior in the Workplace is Both Toxic and Delusional, Report RevealsMarch 30, 2024 | msn.com32 BMW iX EVs were just inducted into this company's fleetMarch 29, 2024 | msn.com"Gen Alpha Needs A Reality Check": 22 Gen Z'ers Were Brutally Honest About The Difference Between Them And Gen AlphaSee More Headlines Receive GMXAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENMAB A/S/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:GMXAY CUSIPN/A CIKN/A Webwww.genmab.com Phone45 70 20 27 28FaxN/AEmployees1,660Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio10.89 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Jan G. J. van de Winkel (Age 58)Co-Founder, Pres & CEO Mr. David A. Eatwell (Age 58)Exec. VP & CFO Mr. Peter Storm Kristensen (Age 44)Associate Director of Legal & Non-Independent Director Mr. Rick Hibbert (Age 39)Associate Director of Protein Production & Chemistry and Non-Independent Director Dr. Judith V. Klimovsky (Age 61)Exec. VP & Chief Devel. Officer Key Competitors4Front VenturesOTCMKTS:FFNTFAbattis BioceuticalsOTCMKTS:ATTBFAesther Healthcare AcquisitionNASDAQ:AEHAWAgentixOTCMKTS:AGTXAlgernon PharmaceuticalsOTCMKTS:AGNPFView All Competitors GMXAY Stock Analysis - Frequently Asked Questions How have GMXAY shares performed this year? GENMAB A/S/S's stock was trading at $31.84 at the beginning of the year. Since then, GMXAY shares have decreased by 10.9% and is now trading at $28.38. View the best growth stocks for 2024 here. How do I buy shares of GENMAB A/S/S? Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GMXAY) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENMAB A/S/S Please log in to your account or sign up in order to add this asset to your watchlist. Share GENMAB A/S/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.